NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Peptide Therapeutics Market Size, Share and Trends Analysis

Global peptide therapeutics market valued at $25.9B in 2023, projected to reach $50.2B by 2032 at 7.8% CAGR. Key drivers include GLP-1 analogs and oncology applications.

Revenue, 2023

$25.9B

Forecast, 2032

$50.2B

CAGR, 2024-2032

7.8%

Report Coverage

North America

Code: peptide-therapeutics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The peptide therapeutics market is experiencing robust growth driven by clinical breakthroughs in metabolic and oncology therapies, with a projected CAGR of 7.8% through 2032.

Market Stage

High growth

Adoption Level

Growing

Key Trends

AI-driven peptide designGLP-1 analog dominanceOral delivery advancementsPersonalized peptide therapeutics
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 7.8%

Base Year (2023)

$27.8B

Forecast (2032)

$50.2B

CAGR (2024-2032)

7.8%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 39.7%CAGR: 7.2%

Largest market: United States

Europe

#2
Share: 30.5%CAGR: 6.8%

Largest market: Germany

03

Market Dynamics

  • Rising prevalence of chronic diseases
  • Advancements in peptide engineering
  • FDA/EMA regulatory support for biologics
  • Increasing investment in biotech R&D
04

Market Segmentation

By Type

  • Linear Peptides
  • Cyclic Peptides
  • Constrained Peptides
  • Peptide-Drug Conjugates

By Application

  • Oncology
  • Diabetes & Obesity
  • Endocrinology
  • Infectious Diseases

By End User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Research Institutions
05

Regional Analysis

1

North America

Lead: United States
CAGR: 7.2%Share: 39.7%

Leading region due to high adoption of premium therapies and strong biotech innovation ecosystem

2

Europe

Lead: Germany
CAGR: 6.8%Share: 30.5%

Robust regulatory framework supporting peptide therapeutics development

3

Asia Pacific

Lead: China
CAGR: 9.2%Share: 27.3%

Rapidly expanding market driven by healthcare infrastructure investments and rising chronic disease burden

Country-Level Analysis

CountryShareGrowth
United States
28.6%
+7.5%
Germany
18.4%
+7.0%
China
15.2%
+10.1%
06

Competitive Landscape

N

Novo Nordisk

Denmark

Leader30.2B

Dominant in diabetes/obesity segment with GLP-1 analogs; aggressive pipeline in oncology peptides

WegovyMounjaroRybelsus
E

Eli Lilly

United States

Leader25.8B

Pioneer in dual GLP-1/GIP agonists; expanding into peptide-based oncology therapies

MounjaroZepboundTirzepatide
A

Amgen

United States

Challenger

Focus on oncology peptides and bi-specific peptide therapeutics

S

Sanofi

France

Challenger

Strong presence in diabetes peptides with proprietary delivery platforms

A

AstraZeneca

United Kingdom

Follower

Investing in peptide-based cardiovascular and respiratory therapies

07

Recent Developments

24
2024Novo Nordisk

FDA approval for Wegovy in pediatric obesity (age 12+)

24
2024Eli Lilly

Launch of Mounjaro for type 2 diabetes in EU markets

23
2023Amgen

Acquisition of peptide engineering startup Peptidomix

23
2023Sanofi

FDA breakthrough designation for peptide-based cancer vaccine

22
2022Regeneron

Partnership with biotech firm for oral peptide delivery platform

08

Regulatory Landscape

FDA's Accelerated Approval Pathway for BiologicsEMA's Enhanced Scientific Advice for Peptide TherapeuticsICH Q11 Guidelines for Peptide Manufacturing
09

Frequently Asked Questions

The market size was valued at $25.9 billion in 2023 and is projected to reach $50.2 billion by 2032.
The compound annual growth rate is estimated at 7.8% from 2024 to 2032.
Diabetes and obesity applications currently hold the largest market share at 35.2%, driven by GLP-1 analogs.
Asia Pacific is the fastest-growing region with a CAGR of 9.2% due to rising chronic disease prevalence and healthcare investments.